Q-omics provides the consensus-scored CHKB-CPT1B profile across patient tissues and cancer cell-line models. CHKB-CPT1B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CHKB-CPT1B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, CHKB-CPT1B RNA expression shows 18,305 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BLCA, and DLBC as cancer lineages where CHKB-CPT1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHKB-CPT1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHKB-CPT1B survival associations across molecular data types. CHKB-CPT1B RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHKB-CPT1B RNA expression–survival associations across cancer types. High CHKB-CPT1B expression shows unfavorable associations in MESO, KIRC, THCA and COAD, but favorable associations in BLCA and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CHKB-CPT1B RNA expression.
This table summarizes CHKB-CPT1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CHKB-CPT1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHKB-CPT1B shows higher tumor expression in BLCA, UCEC, THCA, LUSC, LIHC and STAD. The BLCA box plot shows higher CHKB-CPT1B RNA expression in tumor versus normal tissue (log2 FC = +0.670, t-test p < 0.001).
This table shows molecular features associated with CHKB-CPT1B in patient tissues and cancer cell lines. In patient samples, CHKB-CPT1B shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHKB-CPT1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS.
